Primary Thrombotic Microangiopathy in Pediatric Patients

  • Andrés David Aranzazu Ceballos
  • , Lina María Martínez Sánchez
  • , Ana Paulina Pamplona Sierra
  • , Daniela Vergara Yánez
  • , Liliana Franco Hincapié
  • , Richard Baquero Rodriguez

Producción científica: Contribución a una revista científicaArtículo en revista científica indexadarevisión exhaustiva

Resumen

Background. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology. A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results. Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli, and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion. This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.
Idioma originalIndefinido/desconocido
PublicaciónGlobal Pediatric Health
Volumen11
DOI
EstadoPublicada - dic. 2024

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

  1. ODS 3: Salud y bienestar
    ODS 3: Salud y bienestar

Tipos de Productos Minciencias

  • Artículos de investigación con calidad A2 / Q2

Citar esto